Critical analysis on the use of cholecalciferol as a COVID-19 intervention
a narrative review
Palavras-chave:
Vitamin D, Cholecalciferol, COVID-19 [supplementary concept], Severe acute respiratory syndrome coronavirus 2, [supplementary concept], CoronavirusResumo
BACKGROUND: The World Health Organization has declared that a pandemic situation exists in relation to the disease caused by the new coronavirus, COVID-19. So far, the absence of a vaccine against the new coronavirus has led people worldwide to seek various therapeutic alternatives, including use of cholecalciferol. DESIGN AND SETTING: Narrative review developed by a research group at a public university in Recife (PE), Brazil. METHODS: We searched the literature on the use of cholecalciferol for prevention or treatment of COVID-19, using the MEDLINE and LILACS databases, with the keywords “vitamin D”, “cholecalciferol”, “SARS-CoV-2”, “COVID-19” and “coronavirus”, from January 1, 2020, to June 10, 2020. Narrative reviews, cohort studies and ecological studies were selected. RESULTS: We retrieved 32 references, of which 8 were considered eligible for intensive review and critical analysis. These comprised five narrative reviews, two observational studies and one protocol proposal. Most of the studies selected reported positive effects from use of vitamin D for prevention or treatment of COVID-19. However, there was little quantitative data to assess the real impact of using this vitamin as an intervention against this disease. CONCLUSIONS: Current studies on vitamin D used for purposes other than bone health promotion cannot be taken as support to justify its use in a disease as recent as COVID-19. Studies of greater robustness, with higher levels of clinical evidence, need to be conducted. Rational use of this vitamin needs to be ensured, thereby minimizing the impacts on the patient and the public healthcare system.
Downloads
Referências
World Health Organization. Folha informativa COVID-19 – Escritório da OPAS e da OMS no Brasil. 2020. Available from: https://www.paho.org/bra/index.php?option=com_content&view=article&id=6101:covid19&Itemid=875#vacina. Accessed in 2020 (Sep 14).
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. PMID: 32109013; https://doi.org/10.1056/NEJMoa2002032.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497- 506. PMID: 31986264; https://doi.org/10.1016/S0140-6736(20)30183-5.
Brazilian Federal Pharmacy Council. Survey shows how Covid-19’s fear impacted drug sales [Levantamento mostra como o medo da covid-19 impactou venda de medicamentos]. 2020. Available from: https://www.cff.org.br/noticia.php?id=5747. Accessed in 2020 (Sep 14).
Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol. 2011;50(3):194-200. PMID: 21242105; https://doi.org/10.1016/j.jcv.2010.12.006.
Havers F, Smeaton L, Gupte N, et al. 25-hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings. J Infect Dis. 2014;210(2):244-53. PMID: 24799602; https://doi.org/10.1093/infdis/jiu259.
Gruber-Bzura BM. Vitamin D and influenza − Prevention or therapy? Int J Mol Sci. 2018;19(8):2419. PMID: 30115864; https://doi.org/10.3390/ijms19082419.
Jiménez-Sousa MÁ, Martínez I, Medrano LM, Fernández-Rodríguez A, Resino S. Vitamin D in human immunodeficiency virus infection: Influence on immunity and disease. Front Immunol. 2018;9:458. PMID: 29593721; https://doi.org/10.3389/fimmu.2018.00458.
Teymoori-Rad M, Shokri F, Salimi V, Marashi SM. The interplay between vitamin D and viral infections. Rev Med Virol. 2019;29(2):1-16. PMID: 30614127; https://doi.org/10.1002/rmv.2032.
Brazilian Society of Endocrinology and Metabology. Clarification Note from the Brazilian Society of Endocrinology and Metabology (SBEM) and the Brazilian Association for Bone Assessment and Osteometabolism (ABRASSO): Vitamin D and Covid-19 [Nota de Esclarecimento da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) e da Associação Brasileira de Avaliação Óssea e Osteometabolismo (ABRASSO): Vitamina D e Covid-19]. 2020. Available from: https://www.endocrino.org.br/nota-de-esclarecimento-vitamina-d-e-covid-19/. Accessed in 2020 (Sep 14).
Bartoszynski T, Shelah S. A Note on Small Sets of Reals. C R Acad Sci Paris. 2018;356(1):1053-61. https://doi.org/10.1016/j.crma.2018.11.003.
Leendertse AJ, Van Den Bemt PM, Poolman JB, et al. Preventable Hospital Admissions Related to Medication (HARM): Cost analysis of the HARM study. Value Heal. 2011;14(1):34-40. PMID: 21211484; https://doi.org/10.1016/j.jval.2010.10.024.
Nivya K, Sri Sai Kiran V, Ragoo N, Jayaprakash B, Sonal Sekhar M. Systemic review on drug related hospital admissions − A pubmed based search. Saudi Pharm J. 2015;23(1):1-8. PMID: 25685036; https://doi.org/10.1016/j.jsps.2013.05.006.
Munn Z, Moola S, Lisy K, Riitano D, Tufanuru C. Chapter 5: Systematic reviews of prevalence and incidence. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI; 2020. https://doi.org/10.46658/JBIMES-20-06.
Malta M, Cardoso LO, Bastos FI, Magnanini MM, Silva CM. STROBE initiative: guidelines on reporting observational studies. Rev Saude Publica. 2010;44(3):559-65. PMID: 20549022; https://doi.org/10.1590/s0034-89102010000300021.
Caccialanza R, Laviano A, Lobascio F, et al. Early nutritional supplementation in non-critically ill patients hospitalized for the 2019
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
